Moderna Inc. (MRNA) News
Filter MRNA News Items
MRNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRNA News Highlights
- MRNA's 30 day story count now stands at 22.
- Over the past 24 days, the trend for MRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- EU, SHOT and TRC are the most mentioned tickers in articles about MRNA.
Latest MRNA News From Around the Web
Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.
Moderna's Shares Could Take Off if These 2 Things HappenModerna (NASDAQ: MRNA) used to be a stock market star, climbing 1,700% from the start of 2020 through July of 2021. Investors liked that, and it clearly showed in the stock performance. After all, the vaccine is Moderna's only product right now, and demand for it has declined. |
Here's Why You Should Consider Moderna Stock, and No, It's Not the COVID VaccineOnce a relatively unknown biotech company, Moderna (NASDAQ: MRNA) became a household name when it became one of the first companies to offer a vaccine for the COVID-19 virus. At its peak, Moderna saw quarterly revenue of $7 billion as it sold vaccines to the world. Its stock price followed suit, reaching an all-time high of $484 in mid-2021. |
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment CorporationCAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation (TRC Capital) has amended its unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common ... |
If I Could Only Buy 3 Stocks in 2023, I'd Pick TheseCRISPR Therapeutics (NASDAQ: CRSP) specializes in gene editing, or the repair of faulty genes responsible for disease. Right now, CRISPR is heading for its biggest moment ever -- a regulatory decision on what may become its first commercialized product. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March. |
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential. |
Moderna (MRNA) Outpaces Stock Market Gains: What You Should KnowIn the latest trading session, Moderna (MRNA) closed at $100.27, marking a +0.83% move from the previous day. |
Covid-19 Vaccine Uptake Could Beat Expectations, Poll IndicatesThe consensus view had been that Americans are tired of lining up for the shots. Manufacturers have pulled back from usage estimates made early this year. |
DNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With PfizerThe deal keeps Ginkgo alive, but its business model of becoming the "Apple Store of Biotech" remains unproven. |
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize MedicinePharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in the fight against pathogens. The world learned about messenger RNA molecules and their flexibility, speed and power during the COVID-19 battle. Although this virus is still present, mRNA vaccines helped the world cope with this unprecedented health challenge and move on. But this technology is also |
Is Moderna Stock A Buy As Its Case For A New Flu Vaccine Finally Pans Out?Is Moderna stock a buy after the company announced positive results for its flu shot? Is MRNA stock a buy right now? |